FDA Analyzing Safety of RSV Antibodies Approved for Young Children

The probe is being led by the FDA’s Center for Drug Evaluation and Research.

The U.S. Food and Drug Administration in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times

The Food and Drug Administration is reviewing the safety of antibodies against respiratory syncytial virus (RSV) that have been cleared for use in babies and toddlers.

The probe is being conducted by the FDA’s Center for Drug Evaluation and Research (CDER), according to the government.